A comparison of etanercept vs. infliximab for the treatment of post-arrest myocardial dysfunction in a swine model of ventricular fibrillation

Resuscitation

Volumn 84, Issue 7, 2013, Pages 999-1003

  Youngquist, Scott T ^a   Niemann, James T ^b,c   Shah, Atman P ^d   Thomas, Joseph L ^b,c   Rosborough, John P ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cardiopulmonary resuscitation; Etancercept; Inflammatory response; Infliximab; Post resuscitation period; Ventricular fibrillation

Indexed keywords

ETANERCEPT; INFLIXIMAB; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; GENERAL ANESTHESIA; HEART ARREST; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE FIBRILLATION; HEMODYNAMICS; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; POST ARREST MYOCARDIAL DYFUNCTION; POST ARREST MYOCARDIAL DYSFUNCTION; PRIORITY JOURNAL; RESUSCITATION; RETURN OF SPONTANEOUS CIRCULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; HEART ARREST, INDUCED; IMMUNOGLOBULIN G; RANDOM ALLOCATION; RECEPTORS, TUMOR NECROSIS FACTOR; SWINE; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FIBRILLATION; VENTRICULAR FUNCTION, LEFT;

EID: 84878836341     PISSN: 03009572     EISSN: 18731570     Source Type: Journal    
DOI: 10.1016/j.resuscitation.2012.12.028     Document Type: Article

References (28)

1. Neumar R., Nolan J., Adrie C., et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A consensus statement from the International Liaison Committee on Resuscitation (American Heart Association, Australian and New Zealand Council on Resuscitation, European Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Asia, and the Resuscitation Council of Southern Africa); the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; and the Stroke Council. Circulation 2008, 118:2452-2535.
2. Nadkarni V.M., Larkin G.L., Peberdy M.A., et al. First documented rhythm and clinical outcome from in-hospital cardiac arrest among children and adults. JAMA 2006, 295:50-57.
3. Nolan J.P., Laver S.R., Welch C.A., Harrison D.A., Gupta V., Rowan K. Outcome following admission to UK intensive care units after cardiac arrest: a secondary analysis of the ICNARC Case Mix Programme Database*. Anaesthesia 2007, 62:1207-1216.
4. Adrie C. Successful cardiopulmonary resuscitation after cardiac arrest as a " Sepsis-Like" Syndrome. Circulation 2002, 106:562-568.
5. Ito T., Saitoh D., Fukuzuka K., et al. Significance of elevated serum interleukin-8 in patients resuscitated after cardiopulmonary arrest. Resuscitation 2001, 51:47-100.
6. Kern K., Berg R., Hilwig R., Larson D., Gaballa M. Myocardial cytokine IL-8 and nitric oxide synthase activity during and after resuscitation: preliminary observations in regards to post-resuscitation myocardial dysfunction. Resuscitation 2008, 77:401-410.
7. Niemann J., Garner D. Tumor necrosis factor-α is associated with early postresuscitation myocardial dysfunction. Crit Care Med 2004, 32.
8. Youngquist S., Niemann J., Heyming T., Rosborough J. The central nervous system cytokine response to global ischaemia following resuscitation from ventricular fibrillation in a porcine model. Resuscitation 2009, 80:249-301.
9. Kleinbongard P., Schulz R., Heusch G. TNFα in myocardial ischaemia/reperfusion, remodeling and heart failure. Heart Fail Rev 2011, 16:49-69.
10. Niemann J., Youngquist S., Rosborough J., Shah A., Phan Q., Filler S. Infliximab attenuates early myocardial dysfunction after resuscitation in a swine cardiac arrest model. Crit Care Med 2010, 38:1162-1169.
11. Moe G.W., Marin-Garcia J., Konig A., Goldenthal M., Lu X., Feng Q. In vivo TNF-α inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure. Am J Physiol Heart Circ Physiol 2004, 287:H1813-H1820.
12. Gulick T., Chung M.K., Pieper S.J., Lange L.G., Schreiner G.F. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci U S A 1989, 86:6753-6757.
13. Kao Y.-H., Chen Y.-C., Cheng C.-C., Lee T.-I., Chen Y.-J., Chen S.-A. Tumor necrosis factor-alpha decreases sarcoplasmic reticulum Ca2+-ATPase expressions via the promoter methylation in cardiomyocytes. Crit Care Med 2010, 38:217-239.
14. Song W., Lu X., Feng Q. Tumor necrosis factor-α induces apoptosis via inducible nitric oxide synthase in neonatal mouse cardiomyocytes. Cardiovasc Res 2000, 45:595-602.
15. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., Willerson J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure. Circulation 2003, 107:3133-3140. Investigators ftA.
16. Mann D.L., McMurray J.J.V., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure. Circulation 2004, 109:1594-1602.
17. Kalil A.C., LaRosa S.P., Gogate J., Lynn M., Opal S.M. Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis. Shock 2011, 36:331. the Eritoran Sepsis Study Group.
18. Kohno T., Tam L.T., Stevens S.R., Louie J.S. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J Investig Dermatol Symp Proc 2007, 12:5-8.
19. Skyschally A., Gres P., Hoffmann S., et al. Bidirectional role of tumor necrosis factor-α in coronary microembolization. Circ Res 2007, 100:140-146.
20. Deswal A., Bozkurt B., Seta Y., et al. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999, 99:3224-3226.
21. Bozkurt B., Torre-Amione G., Warren M.S., et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (Enbrel) in patients with advanced heart failure. Circulation 2001, 103:1044-1047.
22. Scallon B., Cai A., Solowski N., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002, 301:418-444.
23. Niemann J., Rosborough J., Youngquist S., Lewis R., Phan Q., Filler S. The proinflammatory cytokine response following resuscitation in the swine model depends on the method of ventricular fibrillation induction. Acad Emerg Med 2008, 15:939-983.
24. Niemann J., Rosborough J., Youngquist S., Thomas J., Lewis R. Is all ventricular fibrillation the same? A comparison of ischemically induced with electrically induced ventricular fibrillation in a porcine cardiac arrest and resuscitation model. Crit Care Med 2007, 35:1356-1417.
25. Spaulding C.M., Joly L.-M., Rosenberg A., et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. NEJM 1997, 336:1629-1633.
26. Niemann J., Rosborough J., Youngquist S. Is the tumour necrosis factor-alpha response following resuscitation gender dependent in the swine model?. Resuscitation 2008, 77:258-321.
27. Meybohm P., Gruenewald M., Albrecht M., et al. Hypothermia and postconditioning after cardiopulmonary resuscitation reduce cardiac dysfunction by modulating inflammation, apoptosis and remodeling. PLoS ONE 2009, 4:e7588.
28. Meybohm P., Gruenewald M., Zacharowski K.D., et al. Mild hypothermia alone or in combination with anesthetic post-conditioning reduces expression of inflammatory cytokines in the cerebral cortex of pigs after cardiopulmonary resuscitation. Crit Care 2010, 14:r21.